In Focus: recent therapies for thyroid cancer
In our latest In Focus, Kate Newbold (Royal Marsden Hospital in London, UK) discusses treatment options for thyroid cancer and their limitations. Newbold also explores how we can overcome these limitations and provides her predictions for how the treatment landscape will evolve over the next few years.
Find out about current treatment options for thyroid cancer such as the recent approval of selpercatinib for patients with an alteration in the RET gene in this interview with Kate Newbold
This infographic explores the current treatment options for thyroid cancer, their limitations and predictions for the future of the treatment landscape.
This news story describes a framework to differentiate between benign and malignant thyroid nodules, which demonstrates the potential of the method to compare different thyroid nodules to a similar level to that of expert radiologists.
This Phase II study published in Future Oncology assesses the safety and efficacy of once-daily lenvatinib in Japanese patients with advanced thyroid cancers.
Tessler chairs the American College of Radiology’s Thyroid Imaging, Reporting and Data System (TI-RADS) Committee, which published a new ultrasound-based scoring system for thyroid nodules, find out more in this interview.